STAT3-IN-36 (compound 11g) is a triple-target inhibitor targeting LRPPRC , STAT3 , and CDK1 with anticancer activity. STAT3-IN-36 binds to LRPPRC, STAT3 , and CDK1 , exerting a stronger anticancer effect than TMF ( HY-N6818 ) or Capecitabine ( HY-B0016 ). STAT3-IN-36 inhibits HGC27 cells with IC 50 1.8 μM..
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Signaling Pathways > STAT
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.